<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<rss version="2.0">
  <channel>
    <title>Rombouts, E.J.</title>
    <link>http://repub.eur.nl/res/aut/13624/</link>
    <description>List of Publications</description>
    <language>en</language>
    <image>
      <url>http://repub.eur.nl/static-eur/img/logo.png</url>
      <title>RePub, Erasmus University Rotterdam</title>
      <link>http://repub.eur.nl</link>
    </image>
    <item>
      <title>Keratinocyte Growth Factor and Stem Cell Factor to Improve Thymopoiesis after Autologous CD34 
                    + Cell Transplantation in Rhesus Macaques (Article)</title>
      <link>http://repub.eur.nl/res/pub/37203/</link>
      <pubDate>2012-01-01T00:00:00Z</pubDate>
      <description>Deficient thymopoiesis and retarded recovery of naive CD4+T cells are important determinants of insufficient immune-competence following hematopoietic stem cell transplantation (HSCT). Although keratinocyte growth factor (KGF) may protect the thymic epithelium, stem cell factor (SCF) is involved in early thymopoiesis. We evaluated whether KGF alone or combined with SCF would affect thymopoiesis and hematologic recovery following myeloablative autologous HSCT into rhesus macaques. Purpose-bred adult rhesus macaques received 106autologous CD34+-selected mononuclear bone marrow cells (BMC)/kg after 9 Gy myeloablative conditioning. Animals were treated with phosphate-buffered saline (PBS) (n = 2), KGF alone (n = 2), or KGF combined with SCF (n = 2). KGF-treated animals showed accelerated hematologic recovery, improved thymopoiesis, and enhanced naive T-cell recovery following transplantation. Improved Tcell recovery was not associated with protection against cytomegalovirus reactivation nor with improved antibody response to tetanus toxoid vaccination. Animals treated with KGF and SCF experienced severe adverse events that precluded evaluation of thymopoiesis and T cell recovery. Collectively, our data confirm that KGF may enhance thymopoiesis. </description>
    </item> <item>
      <title>Human fetal lymphoid tissue-inducer cells are interleukin 17-producing precursors to RORC+ CD127+ natural killer-like cells (Article)</title>
      <link>http://repub.eur.nl/res/pub/14211/</link>
      <pubDate>2008-01-01T00:00:00Z</pubDate>
      <description>The human body contains over 500 individual lymph nodes, yet the biology of their formation is poorly understood. Here we identify human lymphoid tissue-inducer cells (LTi cells) as lineage-negative RORC+ CD127+ cells with the functional ability to interact with mesenchymal cells through lymphotoxin and tumor necrosis factor. Human LTi cells were committed natural killer (NK) cell precursors that produced interleukin 17 (IL-17) and IL-22. In vitro, LTi cells gave rise to RORC+ CD127+ NK cells that retained the ability to produce IL-17 and IL-22. Postnatally, similar populations of LTi cell-like cells and RORC+ CD127+ NK cells were present in tonsils, and both secreted IL-17 and IL-22 but no interferon-γ. Our data indicate that lymph node organogenesis is controlled by an NK cell precursor population with adaptive immune features and demonstrate a previously unappreciated link between the innate and adaptive immune systems.</description>
    </item> <item>
      <title>The novel AML stem cell-associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells (Article)</title>
      <link>http://repub.eur.nl/res/pub/35173/</link>
      <pubDate>2007-10-01T00:00:00Z</pubDate>
      <description>In CD34+acute myeloid leukemia (AML), the malignant stem cells reside in the CD38+compartment. We have shown before that the frequency of such CD34+CD38-cells at diagnosis correlates with minimal residual disease (MRD) frequency after chemotherapy and with survival. Specific targeting of CD34+CD38+cells might thus offer therapeutic options. Previously, we found that C-type lectin-like molecule-1 (CLL-1) has high expression on the whole blast compartment in the majority of AML cases. We now show that CLL-1 expression is also present on the CD34+CD38-stem-cell compartment in AML (77/89 patients). The CD34+CLL-1+population, containing the CD34+CD38-CLL-1+cells, does engraft in nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice with outgrowth to CLL-1+blasts. CLL-1 expression was not different between diagnosis and relapse (n = 9). In remission, both CLL-1-normal and CLL-1+malignant CD34+CD38-cells were present. A high CLL-1+fraction was associated with quick relapse. CLL-1 expression is completely absent both on CD34+CD38-cells in normal (n = 11) and in regenerating bone marrow controls (n = 6). This AML stem-cell specificity of the anti-CLL-1 antibody under all conditions of disease and the leukemia-initiating properties of CD34+CLL-1+cells indicate that anti-CLL-1 antibody enables both AML-specific stem-cell detection and possibly antigen-targeting in future. </description>
    </item> <item>
      <title>Connexin-43 gap junctions are involved in multiconnexin-expressing stromal support of hemopoietic progenitors and stem cells (Article)</title>
      <link>http://repub.eur.nl/res/pub/9397/</link>
      <pubDate>2000-01-01T00:00:00Z</pubDate>
      <description>Gap junctions (GJs) provide for a unique system of intercellular
          communication (IC) allowing rapid transport of small molecules from cell
          to cell. GJs are formed by a large family of proteins named connexins
          (Cxs). Cx43 has been considered as the predominantly expressed Cx by
          hematopoietic-supporting stroma. To investigate the role of the Cx family
          in hemopoiesis, we analyzed the expression of 11 different Cx species in
          different stromal cell lines derived from murine bone marrow (BM) or fetal
          liver (FL). We found that up to 5 Cxs are expressed in FL stromal cells
          (Cx43, Cx45, Cx30.3, Cx31, and Cx31.1), whereas only Cx43, Cx45, and Cx31
          were clearly detectable in BM stromal cells. In vivo, the Cx43-deficient
          14.5- to 15-day FL cobblestone area-forming cells (CAFC)-week 1-4 and
          colony-forming unit contents were 26%-38% and 39%-47% lower than in their
          wild-type counterparts, respectively. The reintroduction of the Cx43 gene
          into Cx43-deficient FL stromal cells was able to restore their diminished
          IC to the level of the wild-type FL stromal cells. In addition, these
          Cx43-reintroduced stromal cells showed an increased support ability
          (3.7-fold) for CAFC-week 1 in normal mouse BM and 5-fold higher supportive
          ability for CAFC-week 4 in 5-fluorouracil-treated BM cells as compared
          with Cx43-deficient FL stromal cells. These findings suggest that stromal
          Cx43-mediated IC, although not responsible for all GJ-mediated IC of
          stromal cells, plays a role in the supportive ability for hemopoietic
          progenitors and stem cells. (Blood. 2000;96:498-505)</description>
    </item>
  </channel>
</rss>